Edition:
United Kingdom

Celon Pharma SA (CLNP.WA)

CLNP.WA on Warsaw Stock Exchange

33.65PLN
21 Sep 2018
Change (% chg)

0.15zł (+0.45%)
Prev Close
33.50zł
Open
33.50zł
Day's High
33.95zł
Day's Low
33.00zł
Volume
927
Avg. Vol
13,064
52-wk High
37.00zł
52-wk Low
27.88zł

Latest Key Developments (Source: Significant Developments)

Celon Pharma Q1 Net Profit Rises To 7.5 Million Zlotys
Tuesday, 15 May 2018 

May 15 (Reuters) - Celon Pharma SA ::Q1 REVENUE 28.2 MILLION ZLOTYS VERSUS 28.4 MILLION ZLOTYS YEAR AGO.Q1 NET PROFIT 7.5 MILLION ZLOTYS VERSUS 5.0 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma Plans FY 2017 Dividend Of 0.17 Zloty/Share
Monday, 7 May 2018 

May 7 (Reuters) - CELON PHARMA SA ::MANAGEMENT PROPOSES FY 2017 DIVIDEND OF 0.17 ZLOTY PER SHARE.  Full Article

Celon Pharma Supervisory Board Chairman Resigns
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - CELON PHARMA SA ::MACIEJ ANDRZEJ KRASINSKI RESIGNS FROM HIS POST AS CHAIRMAN OF CO'S SUPERVISORY BOARD.  Full Article

Celon Pharma To Get PLN 24.7 Mln Financing For Development Of Biosimilar Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - CELON PHARMA SA ::SIGNS AGREEMENT FOR FUNDING OF ITS PROJECT WITH NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT.UNDER AGREEMENT TO GET PLN 24.7 MILLION FINANCING FOR DEVELOPMENT OF BIOSIMILAR DRUG BASED ON FAB FRAGMENT.  Full Article

Celon Pharma Plans To Place Salmex On Scandinavian Markets In H1 2018
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - CELON PHARMA SA ::INFORMS THAT REGISTRATION PROCEDURE OF SALMEX DRUG IN SCANDINAVIAN COUNTRIES ENDS POSITIVELY.ESTIMATES THAT WILL PLACE SALMEX ON SCANDINAVIAN MARKETS IN H1 2018.  Full Article

Celon Pharma Can Start Phase I Clinical Study Of Esketamine-Based Drug
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - CELON PHARMA SA ::GETS PERMISSION FOR STARTING PHASE I CLINICAL STUDY FOR ITS DRUG BASED ON ESKETAMINE.PLANS TO END PHASE I CLINICAL STUDY OF ESKETAMINE-BASED DRUG IN APRIL, 2018.  Full Article

Celon Pharma Q3 net profit down at 4.9 mln zlotys
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - CELON PHARMA SA :Q3 REVENUE 24.2 MILLION ZLOTYS VERSUS 22.4 MILLION ZLOTYS YEAR AGO.Q3 NET PROFIT 4.9 MILLION ZLOTYS VERSUS 7.2 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma to get 25.6 mln zloty financing for its project
Friday, 10 Nov 2017 

Nov 10 (Reuters) - CELON PHARMA SA ::SIGNS DEAL WITH NCBIR UNDER WHICH CO TO GET 25.6 MILLION ZLOTY FINANCING FOR ITS PROJECT.  Full Article

Celon Pharma registers its drug Salmex in Portugal
Friday, 3 Nov 2017 

Nov 3 (Reuters) - CELON PHARMA SA ::ITS DRUG SALMEX GETS REGISTERED IN PORTUGAL, CO CHECKS POTENTIAL OF MARKET AND DRUG COMMERCIALIZATION.  Full Article

Celon Pharma gets US patent on FGFR inhibitors
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - CELON PHARMA SA ::GETS US PATENT ON FGFR INHIBITORS AND THEIR USE IN MEDICINAL PRODUCTS.  Full Article

BRIEF-Celon Pharma Plans FY 2017 Dividend Of 0.17 Zloty/Share

* MANAGEMENT PROPOSES FY 2017 DIVIDEND OF 0.17 ZLOTY PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

No consensus analysis data available.